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Abstract: Population aging is one of the largest challenges of the 21st century. As more people live 
to advanced ages, the prevalence of age-related diseases and disabilities will increase placing an 
ever larger burden on our healthcare system. A potential solution to this conundrum is to develop 
treatments that prevent, delay or reduce the severity of age-related diseases by decreasing the rate 
of the aging process. This ambition has been accomplished in model organisms through dietary, 
genetic and pharmacological interventions. The pharmacological approaches hold the greatest 
opportunity for successful translation to the clinic. The discovery of such pharmacological 
interventions in aging requires high-throughput screening strategies. However, the majority of 
screens performed for geroprotective drugs in C. elegans so far are rather low throughput. Therefore, 
the development of high-throughput screening strategies is of utmost importance. 




Over the last century, improvements in diet, living conditions, education, clean drinking water, 
development of vaccines and medical care have strongly reduced the mortality rate from infectious 
disease, particularly in early life [1,2]. Towards the final decades of the 20th century, medical progress 
started to tackle the diseases of aging, particularly heart disease, leading to a further increase in life 
expectancy [3]. These developments have resulted in a progressive linear increase in life expectancy 
at birth from 48.9 years in 1900 to 79.0 years in 1995 for females born in the US [4–6]. As a consequence, 
the number of elderly people has increased rapidly. At the turn of the 20th century, only 4.1% of the 
US population was 65 or older. By 2014, this number had increased to 14.5%, and it is predicted to 
further increase to 22.1% by the middle of this century [7]. 
The aging process leads to a progressive loss of function and a decline in resilience of the 
organism [8,9]. This in turn increases the susceptibility to a wide diversity of chronic diseases such 
as coronary artery disease, stroke, senile systemic amyloidosis, Alzheimer’s disease, osteoporosis, 
sarcopenia and various cancers [10–13]. Furthermore, the age-related decline in immune function, 
known as immunosenescence, increases the susceptibility to communicable diseases [14]. 
Consequently, aging is the prime cause of disease, disability and death worldwide [15,16]. In recent 
decades, many interventions have been found to increase life- and healthspan in a variety of model 
organisms such as the nematode Caenorhabditis elegans, Drosophila melanogaster, mice and rats. The 
first intervention discovered to increase life- and healthspan was dietary restriction, the act of 
reducing total calorie intake or the intake of specific nutrients without malnutrition [17–19]. This was 
followed by pharmacological and genetic interventions [20–23]. For example, reducing 
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insulin/insulin-like growth factor-1 (IGF-1) signaling resulted in a robust lifespan extension in C. 
elegans, Drosophila and mice [24,25]. These success stories have led to the formulation of the 
geroscience hypothesis: interventions that slow down aging will simultaneously prevent, delay 
and/or reduce the severity of many age-related diseases [16,26,27]. As dietary interventions prove to 
be challenging for most people to adhere to in the long term [28,29] and genetic interventions still 
suffer from many technical, ethical and safety problems [30,31], the main potential in the near future 
for human clinical translation is the development of pharmacological interventions in the aging 
process: so-called geroprotective drugs [22,32–34]. Multiple drugs such as rapamycin, metformin, 
spermidine, senolytics, lithium and acarbose have been found to extend lifespan in model organisms 
[21,22,32,35]. In fact, the first randomized, controlled clinical trial, the TAME (Targeting Aging with 
Metformin) trial, has recently cleared the last obstacle, securing enough funding, and so the trial 
should start in the near future [36]. What makes this trial unique is that it specifically aims to evaluate 
the effects of the drug intervention on the aging process through the use of a composite outcome that 
includes cardiovascular events, cancer, dementia and mortality as a primary endpoint [37]. 
2. Target-Based Versus Phenotypic Screening 
2.1. The Pros and Cons of Target-Based Versus Phenotypic Screening 
While early drug discovery was mostly a serendipitous affair based on observations over 
centuries that certain substances had healing properties in specific diseases, drug discovery became 
more scientific at the beginning of the 20th century [38]. Paul Ehrlich and colleagues synthesized 900 
compounds and systematically screened them in syphilis-infected rabbits for their effectiveness 
leading to the discovery of compound 606, which became known as Salvarsan. Salvarsan was the first 
man-made antibiotic and came into general use in 1910 [39–41]. Currently, the two main paradigms 
in the field of drug discovery are phenotypic screens and target-based screens (Table 1). Other 
methods such as fragment-based screens and virtual screens exist to identify chemical matter that 
likely binds to a functional site within a protein of interest but will not be covered in this review. 
Target-based screens use isolated targets (such as proteins) and screen for compounds that inhibit or 
activate the target by employing a biochemical readout (for example inhibition of catalytic activity of 
the target). In contrast, phenotypic screens employ cell culture, tissues or whole organisms and use a 
phenotype, such as death, as a readout. Before the advent of recombinant gene technology, most drug 
screens employed phenotypic screening. For example, most antibiotics were discovered by screening 
compounds for their ability to kill or inhibit the growth of bacterial cells [42]. Beta-blockers were 
developed by ex vivo studies in heart tissue from guinea pigs [43,44]. Various heat, pressure, electric 
shock or noxious stimulus assays in experimental animals have been used for the identification of 
analgesics [45]. 
The major limitation of phenotypic screens is that the mechanism of action of drug hits is 
unknown and that significant resources might have to be spent in unraveling the mechanism. In fact, 
it has been argued that the difficulty of target identification is the main reason phenotypic screens 
are not more widely used in the pharmaceutical industry [46]. Although knowing the mechanism of 
action is preferable, it is not an absolute requirement for regulatory approval [47]. Indeed, according 
to one study, 7% of known drugs lack a molecular mechanism of action [48]. Furthermore, the 
throughput of phenotypic screens has historically been rather limited, reducing the number of 
compounds that can be screened. 
The advent of ever larger compound libraries has necessitated an increase in throughput, and 
this eventually gave rise to high throughput screening (HTS) in the 1980s. This trend was further 
catalyzed by improvements in: (i) genetic research leading to a rapid expansion in the number of new 
drug targets; (ii) recombinant DNA technology allowing the production of purified recombinant 
proteins for biochemical assays; (iii) assay miniaturization; (iv) the development of liquid handling 
technologies and robotic automation; and (v) advancements in data processing [47,49]. With these 
advances, some companies have started to conduct upwards of 100,000 assays a day, which has been 
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referred to as ultra-high throughput screens [49,50]. HTS can either be cell-based or ex vivo 
biochemical target-based screens [51]. 
In a landmark paper, Swinney and Anthony (2011) analyzed data on FDA drug approvals 
between 1999 and 2008 and found that phenotypic screens are more likely to lead to the discovery of 
first-in-class drugs compared to target-based screening [52]. However, in contrast, another study that 
looked at the drug approvals by the FDA between 1999 and 2013 found that target-based screens 
were responsible for the majority of first-in-class drugs during that period [53]. The limitations of 
pure target-based screening approaches for drug discovery were highlighted by a massive study 
conducted by researchers from GlaxoSmithKline who looked for new antibacterial drugs by running 
HTS screens against 70 targets. This effort took seven years to complete and resulted in only five 
leads, none of which could be progressed further [54]. Many targets identified in the literature are 
insufficiently validated, and this may contribute to the large attrition rates of drug leads during 
animal testing or early clinical trials [55–57]. The target agnostic nature of phenotypic screens can 
also be considered a major strength as it allows for the discovery of truly new therapeutic targets. In 
target-based screening, a drug is optimized for its interaction with a single target, while it is now 
appreciated that some very successful drugs work by being promiscuous for multiple targets that are 
together involved in driving disease pathophysiology [58–61].  
These new insights have led to a revival of phenotypic screening in the last decade [47,62]. While 
earlier phenotypic screens used either cells or mammals (either screening in vivo or on isolated 
tissues), in more recent times, small model organisms such as C. elegans, Drosophila melanogaster, 
zebrafish and Xenopus laevis have been introduced for phenotypic drug screening [63,64]. These 
organisms are smaller and cheaper compared to the use of mammals in phenotypic screening 
campaigns. In addition, the use of invertebrates such as C. elegans and Drosophila raise no ethical 
concerns. Compared to cell-based phenotypic screening, these small model organisms allow for drug 
screening in the context of cell–cell and cell–extracellular matrix interactions under physiological 
conditions [65]. Whole-animal screens provide information about important pharmacokinetic, 
pharmacodynamic, toxicological and off-target activity of the screened compounds at an early stage 
thereby possibly reducing attrition rates during downstream phases of the drug development 
process. As each phase in drug development is more costly than the previous one, the mantra in the 
pharmaceutical industry is to “fail fast, fail cheap” [66]. Furthermore, these small model organisms 
offer the advantage that more complex phenotypes (even behavioral assays) can be used as read-outs. 
Therefore, phenotypic screens in whole organisms are particularly well suited for screens looking at 
ill understood, complex or multisystem diseases such as neurological disorders and aging. Hence, 
small model organisms represent the middle ground between cell-based and mammalian phenotypic 
screens.  
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Table 1. The strengths and weaknesses of target-based versus phenotypic screening in drug discovery. SAR, structure–activity relationship. 
 
Target-Based Screening Phenotypic Screening in Cells Phenotypic Screening in Small Organisms 
(e.g., C. elegans) 
Strengths Weaknesses Strengths Weaknesses Strengths Weaknesses 
Target 
Known target 
selected for screen. 
Cannot find new targets. Target agnostic 
Target identification can be 
cumbersome. 
Target agnostic 




 In vitro study on isolated targets. 
In vitro but on whole 
cells. Cells used can be of 
human origin. Even 
patient-derived primary 




Access to disease relevant cell 
types can be difficult. 
 
Diseases cannot always be easily 
recapitulated in isolated cells 
because they depend on 
interactions of various cells and/or 
systemic factors. 
In vivo, small organisms 
contain multiple cell 
types and even organ 
systems thus better 
capturing disease 
processes that depend on 
cell interactions and/or 
systemic factors. 
Small model organisms 










False positives due to compounds 
that target generic mechanisms 
such as protein synthesis which 
affect the assayed phenotype but 
are not specific enough to be used 
as drug leads. 
 
False positives due to 
compounds that target 
generic mechanisms such 
as protein synthesis which 
affect the assayed 
phenotype but are not 
specific enough to be used 
as drug leads. 
Hit 
identification 
Will identify all hits 
that modify the 
target of interest.  
Hits will include 
molecules that cannot be 
used as drug leads (such 
as cytotoxic 
compounds). 
Initial screen may 
already inform about 
toxicity of compounds 
(cell viability). 
 
Hits already have “drug-
like” properties. 
If the library is screened at high 
concentrations, low-potency effects 
could cloud the interpretation of 
the results.  
Initial screen already 




Hits already have “drug-
like” properties. 
If the library is screened at 
high concentrations, low-
potency effects could cloud 
the interpretation of the 
results. However, if too 
low concentrations are 
used, then no effect may be 
seen because drug 
concentrations in the 
organism tend to be much 
smaller than those in the 
medium. 
 
Toxic compounds are 
eliminated even though 
they might have 
pharmacological 
properties and less toxic 
variants could possibly be 
made. 








Exclusion of hits that have poor 
pharmacokinetic and 
pharmacodynamic properties but 
that could still be amendable to 
medicinal chemistry optimization. 
In addition, lead optimization 
(SAR) can be more difficult. 
 
Exclusion of hits that have 
poor pharmacokinetic and 
pharmacodynamic 
properties but that could 
still be amendable to 
medicinal chemistry 
optimization. In addition, 
lead optimization (SAR) 




Low amounts of 
compound required.  
Low amounts of 
compound required.   





 High throughput   Low throughput 
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2.2. Phenotypic Screening for Geroprotective Compounds 
To improve the translational potential of phenotypic drug screening three criteria for phenotypic 
assays were proposed: assay system, stimulus and readout [56]. The first criterion deals with the 
disease-relevance of the used assay system. Many phenotypic screens have used cell lines that possess 
genetic abnormalities or differ from the cell types in which the disease normally manifests itself hence 
limiting the physiological relevance of the hits obtained from the screen. For example, a group of 
drugs known as correctors for their ability to suppress defects in the intracellular trafficking of the 
chloride channel CFTR induced by the F508del mutation, the most common cause of cystic fibrosis, 
was screened and it was found that the majority of drugs were only active in one of the two tested 
cell lines. Furthermore, of the nine drugs that were active in both cell lines, only two corrected the 
defect in primary human bronchial epithelial cells [67]. The second criterion for phenotypic screens 
is the stimulus employed to evoke the disease phenotype of interest. This can be omitted by using 
assay systems that intrinsically contain the stimulus, such as patient derived primary cells that 
contain the disease-causing mutation. We briefly discuss the use of stress assays in the discovery of 
geroprotective drugs for which the choice of an appropriate stimulus is essential in Section 5.3. For 
example, in C. elegans, heat stress resistance is a better predictor of lifespan than oxidative stress 
resistance [68]. This is likely due to the fact that heat stress resistance is a measure for proteome 
stability, a well-known determinant of longevity [69–71], while the role of oxidative stress in aging, 
particularly in C. elegans, has been questioned [72]. Finally, the assay readout is also imperative. 
Currently, there is a lack of validated readouts for cellular aging that are predictive of organismal 
health or longevity [73]. Therefore, most phenotypic screens that look for geroprotective drugs use 
small model organisms and employ lifespan as the readout. Phenotypes used in these screens should 
be well defined and lifespan is a quantifiable phenotype for which appropriate statistics have been 
developed [46]. As aging is a systemic process that leads to the deterioration of multiple tissues, 
organs and physiological functions, it is better represented by phenotypic screens in small model 
organisms compared to cell-based screens [74]. However, cell-based phenotypic screens for 
geroprotective drugs have been carried out in the past. For example, primary murine embryonic 
fibroblasts from DNA repair deficient Ercc1-/- mice that are very sensitive to cellular senescence when 
grown in atmospheric oxygen have been used to screen for drugs that either kill senescent cells 
(senolytic drugs) or drugs that suppress senescent phenotypes (senomorphic drugs). Cellular 
senescence was measured through the detection of senescence-associated β-galactosidase activity 
with a fluorescent substrate and quantified with the IN Cell Analyzer 6000 leading to the 
identification of HSP90 inhibitors as a novel class of senolytic drugs [75]. Similar cell-based screens 
have been carried out, leading to the identification of KU-60019 [76], cardiac glycosides [77] and 
fenofibrate [78] as senolytic drugs. Recently, over 100,000 small molecules were screened for their 
ability to increase oxidative stress resistance in primary human lung fibroblasts. This effort resulted 
in the discovery of 209 primary hits. After several follow-up assays, the list was reduced to a set of 
32 core hits that were tested for their effect on lifespan in C. elegans, resulting in the identification of 
nine compounds that increased lifespan by around 10–50%. However, seven compounds were found 
to have toxicity issues and one compound fit the criteria for “pan assay interference compounds” 
(PAINS). Hence, the screen resulted in the identification of one prime candidate, the chalcone Gr-4D, 
for follow-up studies [79]. Finally, most recently, a methylation-based clock was developed and used 
to screen for geroprotective compounds in vitro [80].  
Most screens for geroprotective compounds use longitudinal follow-up of death as a readout for 
aging. Such mortality studies have been the gold standard in aging research [81]. However, some 
recent research suggests that health- and lifespan can under some conditions be uncoupled [82–85]. 
Hence, assays that measure certain health parameters such as motility in addition to mortality have 
a great potential in the development of geroprotective interventions.  
A major drawback of phenotypic screening is the exclusion of potential leads with bad 
pharmacodynamic and pharmacokinetic properties such as poor adsorption, rapid metabolism or 
toxicity [47]. Leads with unfavorable pharmacodynamic and pharmacokinetic properties could still, 
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after significant lead optimization, result in new drugs. Furthermore, lead optimization using 
structure–activity relationships (SAR) can be very complicated in phenotypic screening if the target 
remains undiscovered [47]. 
A recent extension of phenotypic screening is high-content screening (HCS), which uses 
automated imaging platforms to record multi-dimensional data such as size, shape, granularity and 
fluorescence of cells [86,87]. For example, a HCS drug screen was conducted in C. elegans to identify 
drugs that induce mitochondrial phenotypes that might be predictive of the longevity potential of 
the tested drug [74]. Four known compounds were screened that increased lifespan by inducing mild 
mitochondrial stress (paraquat, rotenone, doxycycline and oligomycin). It was demonstrated that, at 
life extending concentrations, these compounds caused a decrease in size of the worms and induced 
the expression of the stress reporters, validating the assay. Next, the authors used this assay to test a 
novel ATPase inhibitor, LYC-30904, and found that it indeed induced these mitochondrial 
phenotypes. The compound was subsequently tested for lifespan and found to significantly increase 
lifespan. 
2.3. Target-Based Screens for Geroprotective Drugs 
In the last thirty years, many genes have been identified that, when manipulated, increase 
lifespan in various model organisms [23,88,89]. Several of these genes are evolutionarily conserved 
and present in humans, and they encode proteins that are potentially druggable such as NAD+-
dependent protein deacetylase sirtuin-1 (SIRT1), AMP-activated protein kinase (AMPK) and 
mechanistic target of rapamycin (mTOR) [90–95]. One of the earliest target-based screens for 
geroprotective drugs targeted SIRT1 and led to the identification of several compounds, most notably 
resveratrol, which activate SIRT1 [90]. Next, a high-throughput (290,000 compounds) target-based 
screen for SIRT-1 activators was conducted that led to the identification of various SIRT1 activators 
with a potency of over 1000-times that of resveratrol [91]. The level of nicotinamide adenine 
dinucleotide (NAD+) decreases with age [96–100] and it has been suggested that increasing NAD+ 
levels could improve health in the elderly and maybe extend lifespan [101–103]. Multiple pathways 
consume NAD+ in vivo but especially the CD38 enzyme may be responsible for the age-related 
decline in NAD+ levels [104,105]. At GlaxoSmithKline, a HTS campaign for CD38 inhibitors was set 
up, which resulted in the identification of various weakly active inhibitors. SAR optimization studies 
led to the identification of several potent CD38 inhibitors that were demonstrated to increase NAD+ 
levels when given orally to mice [106,107]. Furthermore, one of these inhibitors was shown to 
improve various markers of health in mice including glucose tolerance, muscle function, exercise 
capacity and cardiac function [108]. 
3. Important Considerations for Geroprotective Drug Screening in C. elegans 
One of the most important parameters in drug development is the absorption, distribution, 
metabolism, excretion and toxicity (ADME-Tox) of leads. In target-based drug development ADME-
Tox considerations are only made after the initial screen, namely during the lead selection and 
optimization phase [109]. However, in phenotypic drug discovery ADME-Tox, properties must be 
considered even before conducting the screen. Here, we briefly discuss the ADME-Tox 
considerations as well as some broader considerations in the development of reproducible 
phenotypic drug screens for geroprotective drugs specifically in C. elegans. 
3.1. Pros and Cons of Drug Screening in C. elegans 
The free-living nematode C. elegans was first introduced as a model organism by Sidney Brenner 
in 1963 [110]. Since then, it has become a very popular model organism due to its many advantages. 
Its small size (adult size ~1.5 mm), high fecundity (300 offspring per unmated hermaphrodite), fast 
generation cycle (~3 days from egg to adult at 25 °C) and cheap culturing conditions make it an 
economical model organism that is ideally suited for high throughput studies. Furthermore, its 
completely sequenced genome, the availability of large mutant collections and RNAi libraries that 
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cover nearly its complete genome and the ease by which it can be genetically engineered make it a 
very powerful model for many forms of research [111]. These genetic tools also simplify the 
investigation of targets and mechanisms of drug hits [112]. The ability to store strains indefinitely in 
liquid nitrogen makes it very economical to maintain large mutant collections and prevents genetic 
drift during continuous subculturing [113]. Despite the large evolutionary distance between C. elegans 
and humans, 41% of the C. elegans genes have human orthologs [114]. Even more remarkable is that 
up to 75% of disease-related genes have C. elegans orthologs [115]. Indeed, several pathways 
modulating the aging process have proven to be highly conserved from C. elegans to humans [20,24]. 
Furthermore, aging C. elegans show multiple pathologies that are similar to those observed in elderly 
humans such as loss of muscle function (sarcopenia), loss of learning ability and increased risk for 
infectious disease [116,117]. The worm also amends itself to the creation of human disease models 
such as Alzheimer’s disease [118,119], Huntington’s disease [120], amyotrophic lateral sclerosis [121], 
Duchenne muscular dystrophy [122,123] and hereditary transthyretin amyloidosis [124]. These 
disease models have been used in multiple drug screens. The study of anatomical defects in C. elegans 
is facilitated by the invariant cell lineage [125,126]. Furthermore, its optical transparency allows for 
in vivo observation of morphology, pathological changes and fluorescent or luminescent reporters 
[127]. C. elegans has also proven to be an excellent model to study toxicity. In general, the ranking of 
compounds for toxicity in C. elegans closely matches that observed in mammals [128]. A major benefit 
of phenotypic drug screening in C. elegans is that toxic leads can be eliminated early on in the drug 
development pipeline. Furthermore, drug metabolism is remarkably similar between C. elegans and 
mammals with Phase I and II enzyme modifications to drug compounds [129]. 
Because of the many advantages that C. elegans offers as a model organism, it has become the 
most popular model in geroprotective drug screening. This is illustrated by the fact that almost 70% 
of drugs listed in the DrugAge database have been tested in C. elegans compared to just 10% in mice 
(https://genomics.senescence.info/drugs/stats.php). However, surprisingly few geroprotective drug 
hits first identified in C. elegans have been validated in other model organisms. One example of a 
geroprotective drug first identified in C. elegans [130,131] and later validated in Drosophila [132] is 
lithium. In contrast, many of the well-known geroprotective drugs such as biguanides were first 
identified in rodents [133–135] and only later shown to also extend lifespan in C. elegans [136–139]. 
The high cost of lifespan studies in mice means that only the most promising leads from screens can 
advance to this stage. We recommend validating the C. elegans hits first in cheaper organisms such as 
Drosophila or turquoise killifish before advancing to mammalian lifespan studies [140,141].  
C. elegans, as with all model organisms, has several limitations as well. For example, it lacks 
many tissues and organs present in humans such as the heart, kidney, liver, lungs and eyes [128,142]. 
In addition, the intestine in C. elegans is the major organ for detoxification and fat storage functions 
that in mammals are carried out by the liver and adipose tissue, respectively [143]. It also lacks an 
adaptive immune system, and, while C. elegans does have an innate immune system, it differs in 
several key ways from the mammalian innate immune system such as the apparent lack of any 
nuclear factor-κB (NF-κB), myeloid differentiation primary response 88 (MYD88) and cytokine 
homologs [144]. These factors limit the use of C. elegans as a model to study inflammation and 
immunosenescence. However, C. elegans does experience an increase in susceptibility to bacterial 
infection with age [117]. C. elegans is fully postmitotic excluding its use for the study of stem cell aging 
and tissue repair. Telomere length is very variable and no correlation exists between telomere length 
and lifespan in C. elegans. Furthermore, telomeres in C. elegans do not shorten with age [145]. Another 
consequence of the lack of mitotic cells in C. elegans is that it is unlikely that senescent cells will 
accumulate with age. However, it should be pointed out that postmitotic cells can go into a “senescent 
cell-like” state [146] and that worms stressed by salt show an increase in β-galactosidase staining 
[147,148], a classical marker of cellular senescence. However, to establish that C. elegans cells can 
undergo cellular senescence would require the measurement of multiple senescence markers [149], 
something that, to the best of our knowledge, has not been done yet. Indeed, SA-β-galactosidase 
staining is not sufficient to prove cellular senescence as quiescent macrophages have also been found 
to be SA-β-galactosidase positive [150]. Many of the classical senescence markers [151] are also not 
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amenable to C. elegans. For example, C. elegans has no ortholog of the p16INK4a protein. In addition, the 
use of other cell cycle markers is not possible due to the postmitotic nature of the C. elegans soma 
[152,153]. 
Another limitation of C. elegans is its small size, making it hard to obtain adequate quantities of 
biomass, especially of older worms, for biochemical assays [154]. Moreover, it is difficult to isolate 
individual cells or tissues for biochemical or gene expression analysis. However, it is possible to 
cultivate isolated cells from embryos or larval stages and induce their in vitro differentiation [155–
157]. In addition, FACS sorting of cells obtained from dissociated larvae can be performed [158,159]. 
The lack of commercial antibodies against most C. elegans antigens combined with the fact that many 
proteins in C. elegans are divergent enough from their vertebrate counterparts to preclude the use of 
vertebrate antibodies is also a disadvantage of this organism [160]. 
Finally, C. elegans has evolved specific adaptations to its ecological niche that are not conserved 
in mammals such as the dauer diapause [161,162]. The fact that C. elegans exists as populations of self-
fertilizing hermaphrodites may have important implications for the evolution of their longevity. In 
fact, it has recently been suggested that in C. elegans, in contrast to most other species, aging may have 
evolved as an adaptation [163–165]. 
3.2. Genetic Background of C. elegans 
First, the genetic background of the worm in which the screening takes place should be precisely 
known. For example, the Bristol N2 hermaphrodite strain from CGC is generally considered the wild-
type (WT) strain, but in 2018 a user reported that this N2 strain contained the alh-2(ot588) mutation 
(https://cgc.umn.edu/strain/N2). Recently, the Gems lab reported that the Bristol N2 male stock from 
CGC contains the fln-2(ot611) mutation [166]. These findings have been confirmed by our lab 
(unpublished findings). To avoid genetic drift, it is recommended to regularly thaw new stock. Newly 
thawed worms should be cultured for at least three generations after thawing before being used in 
experiments to remove epigenetic marks caused by the freezing and thawing procedure [167].  
3.3. Effect of Bacteria on Administered Drugs 
Most laboratory studies use live E. coli OP50 rather than killed bacteria as the food source for the 
worms [168,169]. This method introduces the complexity that bacterial metabolism of the drug 
compounds can decrease the drug efficacy by conversion of the drug into inactive metabolites, 
activate the drug leading to higher activity or side activities (e.g., toxicity) can occur (Figure 1) [170]. 
The interference of the bacteria on drug action can be avoided by using dead bacteria (e.g., heat killed) 
[171]. Indeed, it has been shown that the drug concentration in the worm’s body is higher when 
grown on dead bacteria compared to live bacteria [172]. Consequently, several geroprotective drug 
studies in C. elegans have used heat killed bacteria as the food source [173–175]. Nevertheless, the use 
of dead bacteria also carries downsides, most importantly, C. elegans growth is strongly impaired 
leading to a delay in development [176]. Moreover, worms grown on arrested or dead bacteria live 
longer [177–179] and this may prevent the discovery of drug hits that act through similar 
mechanisms. Furthermore, the human gut microbiome may be important for the action of several 
drugs [180,181], and, hence, it is likely more relevant to study the effect of orally administered drugs 
in C. elegans in the presence of live bacteria. Metformin was found to increase lifespan of C. elegans 
when grown in the presence of living E. coli OP50 while actually reducing lifespan when grown on 
dead E. coli OP50 [137]. However, the metabolic capacity of a single bacterial species in the C. elegans 
microbiome is still very different from the metabolic diversity of the human gut microbiome. 
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Figure 1. The influence of various biotic and abiotic factors on drug screening in C. elegans. 
3.4. Drug Administration 
Another important variable is the method by which the drug is administered to the worms. In 
solid nematode growth medium (NGM) lifespan experiments, the drug can be either mixed into the 
molten agar or later added as a solution on top of the solidified agar. Factors such as humidity, 
interactions of the drug with the agar and solubility of the compound can all potentially influence 
the real level of exposure of the worms to the drug. In contrast, liquid medium provides a much more 
controllable dosing environment [128]. Supplementing the drug into molten NGM may cause 
degradation of the compound due to the high temperature [182]. Another potential problem with the 
addition of drugs to molten NGM is that the drug will be present when the OP50 lawn is grown on 
the plate. In addition to the risk that the drug gets metabolized before worms are added (see above), 
there is also the risk that the bacterial growth is affected by the presence of the drug leading to an 
unwanted dietary restriction effect. Indeed, studies have found that bacterial growth is impaired on 
NGM plates that contain 5-fluoro-2-deoxyuridine [183,184] or metformin [137]. One study 
investigated five different methods of drug administration to worms and found that the highest 
absorption was achieved when the drug was mixed with the molten NGM and the resulting plates 
were seeded with dead E. coli OP50. In addition, supplying the drug in liquid medium containing 
dead bacteria resulted in high drug concentrations in the worm. Adding the drug as a solution on 
top of solidified NGM plates followed by the addition of dead bacteria resulted in a medium level of 
drug uptake. Finally, mixing the drug in the molten NGM and seeding the plates with live bacteria 
or mixing the drug with live bacteria and spreading that solution on plates resulted in the lowest 
drug concentrations in the worms [172]. If the drug is added as a solution on the surface of the agar 
plate, it will inevitably take time for the drug to diffuse through the solid medium. Not much research 
has been done on this but some researchers incubate plates, on which the drug has been added as a 
liquid solution, for 6–24 h before transferring worms [185,186]. Drug uptake by worms grown on 
NGM plates is sometimes absent while that same drug is taken up when supplied in liquid medium. 
This observation can be explained by noting that NGM is a highly complex mixture of two undefined 
compounds (agar and bactopeptone) that could interfere with drug uptake. The high concentrations 
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of small molecules present in bactopeptone could decrease the solubility of drugs in NGM, leading 
to precipitation of the drug in the plates, which can sometimes be visually seen as “crystal gardens” 
[187]. 
Stock solutions of compounds used for HTS are typically prepared in DMSO as this generally 
solubilizes the majority of drug-like compounds. Cell lines typically do not experience negative 
effects from 0.1% DMSO while biochemical assays can tolerate up to 1–5% DMSO [51]. In C. elegans, 
DMSO has been found to increase mean lifespan in a dose-dependent manner from as little as 0.01%, 
reaching a maximum effect at 0.5% [188]. Similarly, it was found that 0.8–1% DMSO increases lifespan 
of C. elegans in liquid medium by 15% [189]. In contrast, high DMSO concentrations can increase 
mortality [190]. In this study, various drugs were tested at different concentrations, and it was 
observed that for some drugs mortality was increased at the highest tested concentrations. Further 
study showed that it was not the drugs but rather the high DMSO concentrations that was driving 
the increased mortality. Therefore, control worms should receive the same solvent exposure as the 
drug-treated worms [191]. Interestingly, resveratrol failed to extend lifespan in the absence of DMSO, 
while lifespan was extended in the presence of DMSO, probably because DMSO is needed for 
solubility [192]. 
3.5. Drug Stability 
Many organic molecules experience significant degradation upon prolonged storage as 
solutions [193]. DMSO is hygroscopic and thus readily absorbs water from the air leading to a 
decrease in compound concentration over time, a change in compound solubility, an increased rate 
of compound breakdown and a decrease in melting point [193,194]. The melting point of dry DMSO 
is 18.5 °C and hence solutions can be frozen by storing them at 4 °C (or at −20 °C to further reduce 
compound breakdown) [194]. The stability of 778 compounds in 100% DMSO for six months was 
investigated under various storage conditions and then the stability was extrapolated for the next 
four years leading to a degradation of 12%, 21% and 58% for compounds stored at −20 °C under 
argon, −20 °C under air and at +15 °C under argon, respectively [195]. For example, it was noted that 
darkening of a thioflavin T stock solution was associated with a loss of the lifespan extending effect 
and even caused early deaths [196]. Presumably, the darkening was a result of the gradual 
degradation of the compound over time. In addition, repeated freeze/thaw cycles could affect the 
stability of compound solutions. Interestingly, no additional peaks were observed in the HPLC 
chromatograms leading the authors to speculate that the loss of compound may principally be driven 
by precipitation [193]. Indeed, a precipitate was observed in many of the solutions at the end of the 
study. Finally, it should be noted that bioactive molecules that can interfere with assays can leach 
from the plastic storage containers and that this problem likely worsens with increased contact time 
between the plastic and the solution and with increased temperature [197–199].  
3.6. Age of First Drug Exposure 
The age at which drug treatment is started may also be an important variable to consider. The 
administration of drugs during larval stages may interfere with normal development. Furthermore, 
if a drug is administered during the early larval stages, it could potentially induce dauer formation 
[128]. Valproic acid extends lifespan when administered from conception [200], but, in another study, 
where it was administered during the adult phase, no effect on lifespan was found [186]. When the 
effect of 21 lifespan extending compounds was tested starting from either Day 1 of adulthood or Day 
8 of adulthood, it was found that all compounds extended lifespan when started at Day 1 but only 
one extended lifespan when administered from Day 8. Two compounds even caused a significant 
decline in lifespan when administered from Day 8 onwards [201]. In a recent study, metformin was 
administered starting at different time points during the worm’s lifespan. At Days 1 and 4 of 
adulthood, metformin, at all tested concentrations, extended the lifespan of the worm while at Day 
10 it reduced lifespan at all tested concentrations [202]. At Day 8, the effect on lifespan was dose 
dependent. Similarly, when metformin was administered to SHR mice from the age of three and nine 
months, it extended mean lifespan by 14.1% and 6.1%, respectively, but no effect was seen in mice 
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administered metformin from age of 15 months. Furthermore, the mean lifespan of tumor-free mice 
started on metformin from the age of 15 months was significantly decreased by 12.8% [203]. 
3.7. Drug Uptake 
C. elegans has an impermeable cuticle that forms a strong barrier for the absorption of many 
drugs. Mutants have been created that have a more permeable cuticle, which should allow for easier 
absorption of exogenously added compounds in drug screening and toxicity testing [204–206]. C. 
elegans also has an extensive enzymatic detoxification system and likely contains xenobiotic efflux 
pumps [207]. All this makes that drug absorption in C. elegans is notoriously limited. For example, it 
was discovered that fewer than 10% of the over 1000 compounds tested were able to accumulate in 
the worm to concentrations over half of that present in the medium. The authors used this knowledge 
to build a predictive model for drug uptake in C. elegans based on the chemical substructures present 
in the drug molecule [129]. To overcome uptake problems, studies in C. elegans often use very high 
drug concentrations compared to studies in mammalian cell culture. However, the use of high drug 
concentrations adds expense to the screen and could lead to problems such as a lack of solubility of 
some compounds [129]. In addition, if only one concentration is tested, then the use of high 
concentrations may lead to high levels of false negatives due to off-target toxicity. A possible solution 
to this problem is to retest all compounds that show toxicity at a lower concentration [63]. To increase 
uptake efficiency of hydrophilic compounds, they can be loaded into liposomes before administration 
to C. elegans [208].  
3.8. Food Intake 
An important confounder in geroprotective drug screening is the influence of a drug on food 
intake [209]. Reduced food intake has been found to increase lifespan in many model organisms 
including C. elegans, mice and rats [17–19,210,211]. Thus, any drug that reduces the rate of pharyngeal 
pumping will likely extend lifespan simply by reducing the ability of the worm to eat. Hence, food 
intake assays [212] should be performed on all positive hits from these drug screens. Another 
important consideration for conducting lifespan tests is that the method must be optimized to ensure 
that, at no point in time during the lifespan assay, food concentrations become too low and induce a 
dietary restriction effect. Especially, when culturing worms in small volumes such as 96- or 384-well 
plates, food levels can become critically low, if the assay protocol has not been properly optimized 
before starting the screen. 
3.9. Abiotic Factors 
C. elegans is exquisitely sensitive to a wide range of environmental factors such as temperature 
[213], humidity [214], light exposure [215] and population density [216]. In fact, it has been 
demonstrated that the growth rate of C. elegans larvae was significantly accelerated by simply 
wrapping the Petri plates, in which they are cultured, with Parafilm M® [217]. It is also worth noting 
that the effect of interventions can be temperature dependent. For example, rsks-1(ok1255) mutants 
have an increased lifespan compared to wild type at high temperature, but actually live shorter at 
low temperature [218]. The common range of temperatures for growing C. elegans in the lab ranges 
from 15 to 25 °C, whereas most lifespan experiments have been conducted at 20 °C [219].  
Some drug compounds may also strongly change the pH of the medium, thereby affecting the 
effect of lifespan. For example, in a study on the effect of α-ketoglutarate on lifespan in C. elegans, it 
was observed that the stock solution of α-ketoglutarate had a pH of 1.56, which might overwhelm 
the buffering capacity of the NGM, leading to an abnormally low pH of the medium. However, 
adjustment of the pH by titration with NaOH did not influence the lifespan results obtained by α-
ketoglutarate treatment [220]. 
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3.10. Reproducibility and Plate-to-Plate Variability 
Before a full screen is conducted, a smaller pilot screen should be conducted to verify the quality 
of the assay. A variety of positive and negative controls should be included in this pilot screen. 
Positive controls for C. elegans lifespan studies include compounds with known longevity extending 
effects such as rapamycin or RNAi or mutants of well-known longevity genes such as daf-2 or eat-2. 
As a negative control, knockdown or mutants in daf-16 could be used. Typically, in HTS, the assay 
quality is judged by the Z’ factor. A Z’ factor value between 0.5 and 1 is considered excellent, while 
a value below 0.5 indicates that the assay is of moderate to poor quality and may need optimization 
before it can be used in HTS. In case of a sub-zero Z’ factor the assay cannot be used in HTS [221]. 
Furthermore, the Z’ factor is often used during a screening campaign to monitor assay performance 
[222]. 
In screens employing multiwell plates, it is important to consider systematic errors resulting 
from well location due to the inherent heterogeneous spatial design of the plate. In particular, wells 
at the periphery of the plate are susceptible to systematic bias, so-called “edge effects”, due to for 
example evaporation and temperature inhomogeneities [223–225]. Other still uncharacterized factors 
may also play a role such as differences in gas exchange [224]. Therefore, some decide to avoid using 
edge wells at all during screenings [226]. In addition, the addition of distilled water in the void 
between the wells can reduce evaporation and thermal gradients [227]. Controls should ideally be 
located randomly within a plate but most often they are placed in the first and last column of the 
plate. In that case, the influence of the edge effect on these controls can be minimized by alternating 
positive and negative controls [228,229]. 
After a screen is successfully conducted, the positive hits should be validated and quality control 
experiments should be conducted. For example, after an automated lifespan screen (see below), the 
hits could be validated by manual lifespan assays and dose–response experiments can be conducted. 
The chemical identity and purity of the compounds used should also be checked [46]. 
Finally, it is important to notice that reproducible results can only be obtained when all methods 
used are thoroughly standardized between experimental runs. Very minute differences such as the 
way worms are picked from a plate and transferred to a new one can greatly influence the outcome 
of an experiment [230]. The Caenorhabditis Interventions Testing Program has published detailed 
protocols for lifespan experiments in C. elegans [167]. Using these standardized protocols, it was 
demonstrated that variation between three different labs in the effects of ten compounds on lifespan 
was remarkably minor. In fact, using a general linear model, it was found that just 1% of variation in 
the results was attributed to between lab variation [186]. Several other excellent reviews discuss 
potential sources of variation and offer suggestions to improve reproducibility of research in C. 
elegans [171,231]. 
4. Limitations of Manual Lifespan Assays 
Manual lifespan assays when working with worms can either be performed on agar plates or in 
liquid medium. 
4.1. Agar Plate-Based Lifespan Assays 
The standard way of conducting an agar plate-based lifespan assay in C. elegans is by manually 
prodding the worms on a regular basis (either daily or every other day) with a platinum wire or 
eyelash and classifying animals as alive or dead based on movement. In addition, animals that die 
from non-aging related causes are generally censored, meaning they are excluded from the analysis. 
This includes animals that are missing, are accidentally killed by the researcher, desiccated worms 
on the walls of the dish, worms burrowed in the agar and the occurrence of internal hatching or 
vulval rupture [219]. Conducting manual lifespan assays in C. elegans is a repetitive, labor intensive 
process that is subject to observational bias. Observer fatigue could induce variability between plates 
[232]. Furthermore, the repeated manual prodding could result in mechanical damage, especially in 
old fragile individuals, and consequently shorten survival. Indeed, Pitt et al. (2019) observed an even 
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longer lifespan in long-lived daf-2(RNAi) worms assayed by an automated lifespan system compared 
to a manual assay [233]. 
Another important consideration with manual assays is that, during the first 7–10 days of 
adulthood, animals have to be moved to new plates on a daily basis to prevent offspring 
contamination. The use of temperature-sensitive sterile mutants, such as glp-1(e2141), glp-4(bn2) or 
fer-15(b26); fem-1(hc17), or the addition of 5-fluoro-2-deoxyuridine (FUdR), which inhibits 
reproduction, significantly reduces the labor burden of the lifespan assay. Temperature-sensitive 
sterile mutants are fertile at a permissive temperature (15 or 20 °C) but sterility is induced upon 
cultivation at a higher restrictive temperature (25 °C) [219]. Notably, glp-1 has a longer lifespan 
compared to wild type N2 worms, and this increased longevity is dependent on DAF-16 [234,235]. 
Since various geroprotective drugs depend, in part, on DAF-16 for their effect on lifespan [236–238], 
these drugs would have been missed in glp-1 screens as they would not be able to induce a greater 
level of DAF-16 nuclear translocation than what is already achieved by the glp-1 mutation. As a 
consequence, few studies have used temperature-sensitive sterile mutants for geroprotective drug 
screening [131]. FUdR prevents the hatching of eggs and is typically used at concentrations between 
25 and 120 µM [239]. However, while FUdR had no effect on lifespan of wild type worms at 20 °C, it 
has been found to increase mean lifespan in wild type worms grown at 25 °C [240] and in certain 
mutants [241,242]. Additionally, it has been reported that FUdR activates stress response pathways 
[240,243] and increases fat accumulation [241]. It has been reported that in some plant extract 
screenings, larvae were observed when FUdR was used at low concentrations (≤ 50 µM) possibly due 
to interference of the plant extract with the molecular effects of FUdR [171]. Therefore, these authors 
started to use FUdR concentrations of 200 µM and even up to 500 µM in compound screens. However, 
FUdR is expensive so the use of high FUdR concentrations in a screen would be a significant cost 
factor. 
4.2. Liquid Culture-Based Lifespan Assays 
C. elegans can be grown in liquid culture in the absence (axenic) or presence (monoxenic) of E. 
coli as a food source. In this article, we only discuss the use of monoxenic liquid culture as, to the best 
of our knowledge, no large-scale drug screens in axenic culture have been performed. The lab of 
Michael Petrascheck has screened 88,000 compounds in liquid monoxenic culture in 96- and 384-well 
plates, leading to the identification of 115 compounds that significantly increase lifespan [244]. This 
technique offers several benefits over classic solid medium based assays. A major benefit of liquid 
culture screening is that many automated liquid handling robots for multiwell plates are 
commercially available. For smaller academic labs that do not have this equipment, the use of 
multichannel pipettors can also greatly reduce labor compared to solid agar-based lifespan assays. 
Furthermore, liquid screens use less drug compound, which can be a significant cost factor [187]. In 
addition, compounds may not be available in larger quantities. For example, commercial compound 
libraries are typically supplied at low milligram quantities. 
However, liquid culture also has several drawbacks. First, lifespan of worms grown in 
monoxenic liquid culture may be different from those grown on solid medium [179]. Worms grown 
in liquid culture are longer [245] and have a higher incidence of internal hatching [246] compared to 
NGM agar. Liquid culture also induces changes in gene expression [247,248]. Moreover, the health of 
the worm may be adversely affected by continuous swimming in liquid medium. While the effect of 
continuous swimming has not been studied, transient exercise has been shown to induce oxidative 
stress and fatigue during the exercise period [248,249]. While such short-term exercise regimes were 
shown to lead to health benefits probably through hormetic action [248–251], continuous exposure to 
the stress of exercise would be expected to have detrimental consequences. In addition, bacterial 
oxygen consumption can result in oxygen depletion in liquid medium leading in the most extreme 
case to the death of the worms [252]. Worm transfers are very complicated in liquid culture, hence 
the use of FUdR or sterile mutants is required when using liquid medium [239], except in cases 
involving certain microfluidics devices (see below). Finally, it should be noted that discrepancies in 
the lifespan effects of drugs on worms grown in liquid culture versus on NGM plates have been 
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observed. As one example, the drug Mianserin extended lifespan in liquid culture [244] but shortened 
lifespan on NGM plates [253]. 
4.3. Methods to Increase Throughput of Lifespan Assays 
Various modifications to the way that manual lifespan assays are being conducted have been 
implemented to increase throughput. One method is the replica set method (RSM), in which 
representative replicates are kept for each time point at which survival will be scored, in contrast to 
the longitudinal follow-up of the same population that is used in traditional lifespan assays. The 
throughput is increased because the replicate plates can be flooded with buffer causing living worms 
to swim, making differentiation of dead and living worms much faster than touching them with a 
worm pick. After counting, the plate is discarded [254]. Alternatively, workload can be reduced by 
regularly scoring the negative control wells until >95% mortality in those wells is observed. When 
this time point is reached, the drug-treated wells are examined and only wells in which live worms 
remain are scored. Using this method, one study group was able to screen 30,000 compounds, an 
effort that resulted in the identification of 500 primary hits, 180 of which were selected for re-testing 
and ultimately led to the identification of 57 compounds that reproducibly increased longevity. The 
authors of this work also noted that it may be useful to re-score the drug wells at the time point when 
>99% mortality is reached in the control wells. Furthermore, if the screen is especially high 
throughput, labor can be reduced by performing the initial scoring at the >99% mortality time point 
[255,256]. 
A common strategy used in both target-based and phenotypic drug screening to increase 
throughput is to pool compounds. For example, in a screen for compounds that enhance 
neurogenesis, 1000 compounds were tested by injecting pools of ten compounds in the ventricles of 
the brain of living mice. Each pool was injected in two mice, hence the whole screen used only 200 
mice [257]. However, such a multiplexing strategy carries various risks such as chemical interaction 
of the pooled compounds, solubility problems, and possible synergetic or antagonistic effects 
between pooled compounds [258–260]. For example, the presence of an acutely toxic compound in 
the pool would be expected to completely mask the beneficial effect of a geroprotective drug present 
in the same pool. One solution that has been employed to overcome these limitations is to include 
each compound in more than one pool [261]. 
Manual assays are also sensitive to variations in environmental conditions. For instance, the 
plates need to be removed from the incubator for scoring, potentially resulting in unintended 
exposure to environmental contaminants. In addition, as the lifespan of C. elegans is very temperature 
sensitive, variations in external temperature can influence the experiment [213]. In contrast, 
automated lifespan devices can be kept for the whole duration of the experiment in a temperature-
controlled incubator, eliminating the influence of temperature or environmental variation between 
conditions and replicates [262]. In a study on the automated NGM based WormBot platform, no well 
to well variation in lifespan was observed and it was demonstrated that the average temperature 
variation between the wells and the surrounding environment remained limited to just 0.04 °C [233]. 
C. elegans lifespan is also sensitive to light exposure [215], and light exposure can be quite variable 
during manual scoring if not properly controlled by the investigator. While the overall level of light 
exposure is higher in typical automated lifespan set-ups, the exposure is at least very consistent 
between conditions and replicates. 
4.4. However, Manual Assays also Have Some Strengths 
While manual lifespan assays suffer from various limitations (as detailed above), it should be 
noted that they also offer several strengths compared to automated lifespan devices (discussed 
below). For example, because the plates are monitored manually, deviations could be spotted such 
as contamination, food depletion or drying out of the plate. It also allows for censoring of worms that 
die from non-aging related causes. In automated systems, such censoring is only possible in case of 
manual post-hoc data analysis. Examination of the plates by eye could also uncover unexpected 
phenotypic differences (such as differences in movement) or differences in health. Manual lifespan 
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assays allow for complex designs such as transfer of the worms to new drug treated plates at specified 
moments or switches between liquid and solid medium. However, probably the most significant 
benefit of manual lifespan assays is that the use of FUdR or sterile mutants to avoid generational mix-
up can be completely avoided by applying manual transfer of worms to fresh plates. 
5. Automated Phenotyping and Lifespan Devices  
Because of the limitations of manual survival assays, automated methods for lifespan 
determination have been developed. These automated lifespan assays offer several distinct benefits 
over manual assays, such as increased temporal resolution and an increased number of technical and 
biological replicates that can be run (Table 2). However, they may also introduce new challenges such 
as temperature gradients produced by various electronic and electromechanical parts. This may 
especially become a problem if the goal is to miniaturize the assay as much as possible (for example, 
growing worms in 384-well plates). 
Table 2. A comparison of the various automated lifespan machines for C. elegans. NGM, nematode 
growth medium; FUdR, 5-fluoro-2-deoxyuridine. 
 Manual Wormbot 
Automated Lifespan 
Machines 





NGM Modified version of NGM NGM Liquid 
See manual, 
assay in liquid 
FUdR Optional Needed Needed Needed Not needed 
Generally 
needed 
Throughput Very low 
High (144 
wells) 




on used chip) 
Very high (96- or 
384-well plates) 
Temporal 


















No Yes Yes Yes Depends Yes 
Contamination can be a risk in long-term cultures and hence many studies that use automated 
lifespan devices add antibiotics and/or antimycotics to plates, wells or microfluidic chips to prevent 
bacterial or fungal contamination [232,233,263,264]. The use of the streptomycin-resistant E. coli 
OP50-1 strain allows the addition of streptomycin to the medium to prevent bacterial contamination 
[265]. However, one should be wary of adding extra chemicals such as antibiotics or antimycotics to 
C. elegans cultures, as these could interfere with the experiment in unexpected ways. Rigorous 
maintenance of sterile technique is the most important recommendation to prevent contamination. 
One of the biggest hurdles to the development of automated HCS platforms for C. elegans is 
automated image capturing and processing. Software must be able to distinguish worms from debris 
and, even more challenging, to “untangle” clusters of worms. Worms expressing a fluorescent protein 
in their pharynges can be used to enhance discrimination of individual worms [232]. 
In manual lifespan assays, death is determined by failure to respond to touch-provoked 
movement. However, this metric is not possible in automatic systems. Such systems generally 
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depend on the determination of the last time point at which a worm still showed spontaneous 
movement [262] or by inducing movement through a short flash of blue light [263]. 
New automated systems should always be validated by comparing lifespans with those 
obtained with manual assays. If any deviations between the two methods are found, then in depth 
studies should quantify which factors are responsible for the observed differences. Furthermore, trial-
to-trial variability should be measured to investigate reproducibility of the method [266]. 
We broadly divide the various automated lifespan devices in two main categories: (1) those 
based on microfluidic chips; and (2) those based on solid agar culture. We discuss stress-based 
screens in a separate heading but most of those methods are based on either microfluidic or solid 
agar lifespan devices except for one notable exception, the recently developed LFASS assay. 
5.1. Microfluidics-Based Platforms 
Microfluidic worm chips are made from polydimethylsiloxane (PDMS). PDMS is a type of 
“silicone” that is non-toxic, chemically inert, permeable to oxygen and carbon dioxide and optically 
transparent for wavelengths over 230 nm, allowing for brightfield and fluorescence microscopic 
imaging of the worms. PDMS adheres tightly to glass surfaces, and hence worm chips are commonly 
mounted on glass microscope slides. The chips are produced by a soft lithography technique. Food 
can be added at user defined time points (e.g., once a day) [246,267] or continuously through the use 
of automated pumps [264]. 
Various microfluidics chips for lifespan assays have been developed including Lifespan-on-a-chip [246] 
and WormFarm [264]. The Lifespan-on-a-chip device consists of an array of chambers that house individual 
worms. This device allows for the longitudinal monitoring of individual worms [246]. Most recently, a 
microfluidics device called NemaLife was designed that includes a micropillar arena. This arena allows the 
worms to crawl as they do on agar plates, rather than swim as in typical microfluidics devices [267]. This device 
also contains sieve channels, but, because the adults generally remain in the micropillar area, the risk of 
physically damaging them is reduced. Furthermore, this device allows for the evaluation of two healthspan 
markers, pharyngeal pumping and vibration-induced locomotion, assays that have to be conducted manually 
[267]. A commercialized version of the NemaLife microfluidics chip combined with a benchtop machine that 
regulates fluid flow through the chip and enables time-laps image recording and analysis has been developed 
(https://www.nemalifeinc.com/). Similarly, a device called the stress-chip combines crawling and swimming 
areas [268]. It should be mentioned that, to the best of our knowledge, no large drug screens in microfluidic 
devices have been conducted so far. We refer the reader to two excellent reviews on the various microfluidic 
platforms for HTS in C. elegans [266,269]. 
One downside of these microfluidic devices is that bacteria can get stuck to the walls, obscuring 
the visualization of the worms and resulting in clogging of the channels. Coating the inside of the 
chip with 2-[methoxy(polyethyleneoxy)6-9propyl] trimethoxysilane, or Pluronic® F-127 reduces the 
adhesion of bacteria to the channel walls [246,270,271]. Clogging can also occur due to precipitation 
of bacteria in the inlet reservoir. This can be avoided by replacing the bacterial suspension in the inlet 
reservoir daily. The fresh bacteria suspension should be filtered, to further remove any particulates 
that could clog the microfluidic channels, prior to loading in the inlet reservoir [246,271]. Some 
investigators have also placed a tiny magnetic stir bar in the syringe containing the bacterial 
suspension to prevent precipitation of the bacteria [270]. As noted above, contamination is a potential 
risk in long-term C. elegans culture in microfluidic devices. These PDMS microfluidic chips can be 
sterilized by autoclaving [269], a 5-min rinse with 70% ethanol [267] or by a combination of ethanol 
and UV treatment [272]. In addition, as explained above, antibiotics and/or antimycotics are 
frequently added to reduce contamination risk [265]. Microfluidics devices can also be used in 
combination with sterile axenic medium, which prevents bacterial metabolism of drugs (see Section 
3.2) as well as biofilm formation inside the microfluidics device [272]. A major limitation of 
microfluidics technology is that it requires specialized equipment and expertise that is not available 
to most C. elegans laboratories. Furthermore, most aging studies have been conducted on agar plates 
and hence data obtained through microfluidic platforms cannot easily be compared to existing 
knowledge. 
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A major benefit of microfluidic devices is that the use of FUdR or sterile mutants can be avoided. 
Eggs and hatched L1s are simply washed away continuously through sieves that prevent adults from 
escaping. However, adult worms can get injured by being pushed against the sieve channels and 
these narrow sieve channels are also at risk of getting clogged [264,273]. As discussed above, the 
recently developed NemaLife system reduces the chance of physical damage to the worms from 
contact with the sieve channels [267]. 
Microfluidic devices offer the ability to track individual worms longitudinally, permitting 
insights into intra-individual variability in responses [270]. A very significant contributor to the 
overall cost of various systems is the quantity of chemicals and/or drugs required. Microfluidic 
methods greatly reduce the quantity of chemicals and/or drugs required thereby reducing the overall 
cost of the screen [264]. Furthermore, it was found that pharyngeal pumping rates are better 
maintained with age in the NemaLife microfluidics device compared to worms grown on agar, a 
feature that may result in better uptake of drugs by old worms [267]. In agar-based lifespan assays, a 
significant proportion of the population can be lost due to burrowing into the agar or crawling up 
the side wall followed by death due to desiccation [186]. As such deaths are censored, it becomes a 
question whether the lifespan data obtained from this selected subset are truly representative for the 
population as a whole. Microfluidics devices eliminate these two sources of death and therefore 
might more accurately capture whole population lifespans [267]. 
Liquid culture of C. elegans offers several distinct benefits over solid plate culture. First, the 
concentration of the bacterial food can be very precisely controlled in liquid culture. Bacterial 
concentration greatly influences the lifespan of C. elegans [179] and consequently drug lifespan 
experiments. Bacterial food concentrations and environmental conditions, such as the presence of 
metabolites and waste products from the worms and bacteria, change over time in agar plate-based 
assays. Periodic transfer of the worms to new plates can minimize changes in the environment but 
the transfer also introduces other problems such as loss of worms or physical damage [268]. In 
contrast, microfluidic systems that use continuous flow of fresh bacterial solution through the worm 
chambers keep food concentrations and environmental conditions constant [246]. Furthermore, they 
allow for downstream sampling and analysis of metabolites and chemicals (such as pheromones) as 
well as progeny produced by the worm [267,271]. 
5.2. Solid Medium-Based Platforms 
In solid medium-based platforms, worms are cultured on NGM and tracked by flatbed scanner-
based or camera-based imaging. Several flatbed-based automated lifespan machines have been 
developed including the lifespan machine [262], WormScan [274] and most recently an automated 
version of WormScan [275]. The lifespan machine is based on a modified flatbed scanner 
(http://lifespanmachine.crg.eu/lsm/). Flatbed scanners are cheap compared to dissecting 
microscopes, and their box-shaped dimensions allow for easy storage in temperature-controlled 
incubators [262]. A major limitation of the lifespan machine is that a modified version of NGM, in 
which CaCl2 is omitted, should be used to increase optical transparency [262]. The use of calcium-
depleted NGM makes it difficult to compare the results obtained by this device with previous 
literature data that used regular NGM. The height of the NGM in the Petri plates also has to be 
controlled carefully so that the surface falls in the focal plane of the scanner [262]. The lifespan 
machine is not able to capture young, fast-moving worms, due to the difficulty in image capturing. 
However, as the worms age, their movement slows down and then the scanner is able to pick them 
up. The inability to detect young worms has apparently no ill effect on the reported lifespan of the 
population [262]. The lifespan machine exposes worms to intense blue/UV light, which, especially in 
the presence of photosensitizers, could influence C. elegans lifespan. Many drugs contain UV-
absorbing moieties, such as benzene and heterocyclic rings, and are thus potentially susceptible to 
the introduction of phototoxicity. Drug compounds could also undergo photodecomposition that 
might result in the formation of toxic molecules [276]. For instance, thioflavin T extends lifespan of 
C. elegans in manual assays, but in the lifespan machine thioflavin T shortened lifespan significantly. 
The adverse effect of thioflavin T on lifespan in liquid cultures was reversed when a blue/UV light 
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filter was installed on the lifespan machine [220]. Another problem is the heat produced by the 
scanner. The scanner used in the lifespan machine uses fluorescent bulbs, which produce more heat 
than LEDs. However, switching to scanners that use LEDs can reduce this problem [268]. The 
software for the lifespan machine is freely available and recently an improved version was released 
in beta (https://github.com/nstroustrup/lifespan). 
WormBot is an open-source robotics platform made from consumer hardware that employs a 
camera attached to an XY plotter to track worms in NGM-filled twelve-well plates [233] 
(http://wormbot.org/). The recorded images can be analyzed by an automated software program. 
WorMotel uses NGM-filled microfabricated well plates and is able to individually track 240 
worms for over two months. The device is able to image the worms either continuously or 
intermittently, and both spontaneous and blue light-induced movement can be measured. The time 
of death is recorded as the last moment of movement [263]. WorMotel can also be used to evaluate 
activity-based healthspan measures [263,277]. Software for the WorMotel is freely available 
(https://github.com/cfangyen/wormotel). 
Automated survival platforms require that worms are cultivated for prolonged periods of time 
on the same NGM plates or wells. This can lead to several problems such as dehydration of the agar, 
fungal growth and fogging of the plate lids. In the lifespan machine, the latter problem is 
circumvented by placing the plates upside down, without a lid on the glass surface of the scanner. 
The temperature gradient generated by the heat produced by the scanner greatly reduces fogging 
issues of the glass scanner surface, but, as an additional precaution, the glass scanner surface can be 
coated with an anti-fog coating such as Rain-X [262]. Similarly, fogging of plate lids can be a problem 
for systems that rely on closed plates, such as Wormbot, and one trick to alleviate this problem is the 
treatment of the lids with detergent solution, such as Tween-20 [278]. To prevent fungal growth 
nystatin is often added to the NGM [262]. 
The C. elegans Interventions Testing Program (CITP) uses Lifespan Machines for increased 
throughput in compound screening (https://citp.squarespace.com/). Thus far, this program, which 
was initiated in 2013, has evaluated more than 20 compounds and found several compounds that 
increased lifespan in at least one of the tested strains [186,220,230,279–281]. 
Several Contract Research Organizations (CROs), such as Magnitude Biosciences Ltd. 
(https://magnitudebiosciences.com/) and InVivo Biosystems (https://invivobiosystems.com/), have 
started to offer solid medium-based automated healthspan and lifespan assays. 
5.3. Stress-Based Platforms 
Increased stress resistance is a commonly observed phenotype of many long-lived C. elegans 
mutants [282–284]. This observation has led to the suggestion that stress resistance screens could be 
used to identify novel long lived mutants [285,286] as well as new geroprotective drug candidates 
[287]. Indeed, several drugs that increase lifespan in C. elegans have been shown to increase resistance 
to various stressors [288,289]. In a recent study, around 100,000 small molecules were screened for 
their ability to induce increased resistance to oxidative stress in a primary human fibroblast cell line. 
This screen resulted in a core set of 32 molecules that were subsequently tested for lifespan in C. 
elegans and resulted in the identification of nine molecules that increased lifespan [79]. 
Screening for increased stress resistance in C. elegans as a predictor for lifespan offers the benefit 
of substantially reducing the assay time. For example, a typical C. elegans lifespan experiment takes 
3–4 weeks to complete, while acute stress survival screens can last from a couple of hours to several 
days depending on the type and severity of the stress applied. We refer the reader to a recent review 
covering the different stressors that can be employed in stress assays in C. elegans [219]. The first high-
throughput stress survival assay in C. elegans employed the vital stain SYTOX green [290]. This 
membrane impermeable dye is excluded from viable cells but readily stains dead cells by 
intercalation in the DNA [291]. A modified version of the SYTOX survival assay was used to identify 
compounds with antimicrobial properties. Worms were infected with the pathogen E. faecalis, and a 
screen with over 37,000 compounds was conducted leading to the identification of 28 compounds 
with anti-microbial properties [292]. Importantly, the concentration at which some of these 
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compounds improved survival in the worm was significantly lower than the concentration needed 
to inhibit bacterial proliferation in vitro. This demonstrates the power of phenotypic screens in C. 
elegans to identify compounds that would have been missed by more traditional screens that use 
growth inhibition or death of isolated bacteria as the read out. It should be noted that a small fraction 
of worms that appear dead by visual inspection may not be SYTOX stained, while some alive worms 
may be stained. This could be caused by SYTOX staining of necrotic cells in living animals, variability 
in the staining, autofluorescence or some compounds may increase the permeability of the 
membranes to the SYTOX dye [292]. Stress screens can also be conducted using automated platforms, 
as discussed above. For example, the lifespan machine was used to evaluate heat and tert-butyl 
hydroperoxide (t-BuOOH) stress resistance [262] and WormBot was used to investigate HCN stress 
resistance between different mutant strains [233]. 
Recently, an automated label-free, HTS platform to assay stress resistance in C. elegans was 
developed [68]. This assay is based on the naturally occurring burst of blue autofluorescence that 
accompanies death in C. elegans [293,294]. This autofluorescence can be quantified with a plate reader. 
This method offers extraordinarily high temporal resolution (up to one measurement every 2 min) 
combined with a high throughput, as 96- or 348-well plates can be used. The authors demonstrated 
that this setup can be employed for multiple stress resistance assays including heat, oxidative stress 
and bacterial pathogen stress. Hence, this approach should lend itself to not only screening for drugs 
that increase stress resistance, but also for anti-infective drugs and anthelmintic drugs. However, 
thus far, no published reports exist that have employed this assay for drug screening. 
It should also be noted that microfluidics devices have been used for stress survival tests in C. 
elegans [268,273]. For example, a microfluidics device was used to test the effect of polydatin and (+/−)-
α-Tocopherol on lifespan, both in unstressed and Cu2+-stressed conditions, validating this device for 
its use in drug screenings [273]. 
6. Future Outlook 
The rate of discovery of new geroprotective drugs has increased significantly since the 1990s. 
This is probably the result of multiple factors including the increased use of short-lived models (such 
as C. elegans) and the introduction of screening methods with increased throughput [295,296]. An 
analysis of the DrugAge database suggests that many known pathways involved in aging have not 
yet been targeted pharmacologically, suggesting opportunities for the discovery of novel 
geroprotective drugs [296]. Throughput of phenotypic screens using whole organisms, such as C. 
elegans, is obviously lower compared to cell-based or target-based screens. However, in our opinion, 
phenotypic assays are better suited for the identification of geroprotective drugs due to the lack of 
validated targets. While hundreds of genes that influence the aging process have been found in small 
model organisms, only a few genes have, thus far, been validated in humans [297,298]. 
However, the use of automated phenotypic screening of small model organisms comes with 
some challenges. A major challenge in automated image-based C. elegans survival assays is the 
difficulty for the software to distinguish individual worms in worm clusters [232,299]. Furthermore, 
when the image data from WormBot were analyzed using a fully automated software program, it 
resulted in longer survival compared to manual annotation of the images or traditional hand scoring 
[233]. The reason for this discrepancy is not yet known. In addition, the data storage capacity required 
for HCS in C. elegans should not be underestimated [233]. 
Another major challenge in the field remains the validation of the numerous lifespan-extending 
drugs that have been discovered in C. elegans in other models such as rodents. In addition, as life- 
and healthspan can, under certain conditions, be uncoupled, it will be paramount to investigate the 
effects of newly identified geroprotective drugs on healthspan [82–85]. Such investigations are 
severely lacking as lifespan studies vastly outnumber healthspan studies [300]. Various healthspan 
measures have been developed in C. elegans; most of them are based on locomotion such as maximum 
speed, number of body bends and bending angle. [82,84,301]. Therefore, the development of systems 
that incorporate the automatic quantification of both healthspan parameters and lifespan will be 
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paramount. Some microfluidics-based [302] and NGM-based [233,277] automated screening 
platforms already enable the simultaneous determination of lifespan and healthspan. 
The development of geroprotective drugs by aid of using model-based screens has the potential 
to deliver significant economic and societal benefits [303,304]. 
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